Puma Biotechnology Q1 net loss $3.4M, product revenue down 11% to $40.7M

PUMA BIOTECHNOLOGY, INC.

2022-Q1 EPS reported -$0.08 revenue$45,736,000

GAAP net loss of $3.4M ($0.08 per share) vs net income of $16.5M ($0.41) in Q1 2021.
Total revenue $45.7M vs $98.2M; product revenue $40.7M (down 11% YoY); royalty revenue $5.0M.
Non-GAAP adjusted net loss $0.3M ($0.01 per share) vs adjusted net income $22.4M ($0.56) a year ago.
Cash and marketable securities $73.9M at March 31, 2022, down from $82.1M at Dec 31, 2021.
Upcoming milestones for neratinib trials: SUMMIT Phase II data in HER2-mutated breast cancer and biliary tract cancer H1 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.